Sorafenib to Treat FLT3-ITD AML

Sorafenib to Treat AML Patients With FLT3-ITD Mutation: a Non-interventional Cohort Study

It is a prospective, non-interventional, open-label study, in order to observe the safety and response in FLT3-ITD mutation positive AML patients who receiving sorafenib as induction, consolidation, salvage, maintenance or alleviative treatment. The duration of the study from June 2014 through May 2019, with the recruitment duration from June 2014 to May 2017. The inclusion criteria is:

1. Definitely diagnosed as AML
2. FLT3-ITD mutation has been confirmed
3. Accepting the prescription of sorafenib

Inclusion Criteria:

• Definitely diagnosed as AML
• FLT3-ITD mutation has been confirmed
• Accepting the prescription of sorafenib

Exclusion Criteria:

• Can not take drugs orally
• Can not follow the doctors' advices
• Other reasons that investigators considered as contra-indications for this study